Status:
COMPLETED
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma
Lead Sponsor:
Pfizer
Conditions:
Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).
Eligibility Criteria
Inclusion
- Have confirmed mantle cell lymphoma diagnosis.
- Have measurable disease.
- Have received at least 2 prior treatment, which may include stem cell transplant.
- Have adequate organ and bone marrow function.
- There are other criteria--please discuss with your doctor.
Exclusion
- Had any prior treatment with temsirolimus or mTOR inhibitor.
- Had allogeneic stem cell transplant within last 6 months and on immunosuppressive therapy.
- Has active or untreated brain or central nervous system metastases.
- There are other criteria--please discuss with your doctor.
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2018
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT01180049
Start Date
March 1 2011
End Date
June 1 2018
Last Update
May 20 2019
Active Locations (31)
Enter a location and click search to find clinical trials sorted by distance.
1
Mercy Research Institute
Miami, Florida, United States, 33133
2
Veterans Affairs New Jersey Healthcare System-Hematology/Oncology Section (111)
East Orange, New Jersey, United States, 07018
3
Mercy Clinic Oklahoma Communities dba Mercy Clinic Oncology/Hematology-McAuley
Oklahoma City, Oklahoma, United States, 73120
4
Mercy Hospital Oklahoma City-Oncology Infusion
Oklahoma City, Oklahoma, United States, 73120